摘要
目的:研究尼麦角林联合加兰他敏治疗轻中度血管性痴呆(VD)患者的疗效与安全性。方法:2016年3月~2017年10月于我院治疗的180例轻中度VD患者被随机均分为尼麦角林组、加兰他敏组和联合治疗组(接受尼麦角林+加兰他敏),观察各组治疗8周、16周、24周的疗效、不良反应发生情况及治疗后血常规异常发生情况。结果:与治疗前比较,治疗8周、16周、24周后三组日常生活能力量表(ADLS)评分均显著升高,且8周<16周<24周,两两比较均有显著差异;治疗8周、16周、24周后,联合治疗组简易精神状态检查表(MMSE)评分显著升高,且8周<16周<24周,治疗16周、24周后尼麦角林组和加兰他敏组MMSE评分显著升高,且治疗24周的显著高于16周;治疗24周后三组血清乙酰胆碱酯酶(AchE)水平均显著降低(P均<0.01)。与尼麦角林组、加兰他敏组比较,联合治疗组治疗8周、16周、24周后ADLS评分[24周:(51.05±6.00)分比(51.67±6.06)分比(56.00±5.53)分]依次显著升高,治疗24周后血清AchE[(60.91±2.45)ng/ml比(60.76±2.51)ng/ml比(59.28±2.30)ng/ml]水平降低更显著(P均<0.01)。三组治疗24周后TESS评分、血常规异常率比较无显著差异,治疗期间不良反应发生率无显著差异(P均>0.05)。结论:尼麦角林联合加兰他敏能更显著地改善轻中度VD患者的认知功能和日常生活能力、降低血清AchE水平,安全性较好。
Objective:To study therapeutic effect of nicergoline combined galantamine on patients with mild-moderate vascular dementia(VD)and its safety.Methods:A total of 180 mild-moderate VD patients treated in our hospital from Mar 2016 to Oct 2017 were randomly and equally divided into nicergoline group,galantamine group and combined treatment group(received nicergoline+galantamine).The therapeutic effect after eight weeks,16 weeks and 24 weeks,incidence of adverse reactions and abnormal blood routine after treatment were observed and compared among all groups.Results:Compared with before treatment,there were significant rise in score of activity of daily living scale(ADLS)in all groups after eight-week,16-week and 24-week treatment,and eight weeks<16 weeks<24 weeks,there existed significant difference between any two time points.There was significant rise in mini-mental state examination(MMSE)score in combined treatment group after eight-week,16-week and 24-week treatment,and eight weeks<16 weeks<24 weeks.There was significant rise in MMSE score in nicergoline group and galantamine group after 16-week and 24-week treatment,and that of 24 weeks was significantly higher than that of 16 weeks.There was significant reduction in serum acetylcholin esterase(AchE)level in all group after 24-week treatment(P<0.01 all).Compared with nicergoline group and galantamine group,there were significant rise in turn in ADLS score[24 weeks:(51.05±6.00)score vs.(51.67±6.06)score vs.(56.00±5.53)score].There were significant reduction in serum AchE level[(60.91±2.45)ng/ml vs.(60.76±2.51)ng/ml vs.(59.28±2.30)ng/ml]after 24-week treatment in combined treatment group(P<0.01 all).There were no significant difference in TESS score,incidence of abnormal blood routine after 24-week treatment and incidence of adverse reactions during treatment(P>0.05 all).Conclusion:Nicergoline combined galantamine can significantly improve cognitive function and daily living ability,and reduce serum AchE level with good safety in patients with mild-moderate VD.
作者
陈康亮
施慧
陈世震
范煜华
向兵
CHEN Kang-liang;SHI Hui;CHEN Shi-zhen;FAN Yu-hua;XIANG bing(Department of Rehabilitation Medicine,Shanghai Zhongye Hospital,Shanghai,200941,China)
出处
《心血管康复医学杂志》
CAS
2020年第2期178-182,共5页
Chinese Journal of Cardiovascular Rehabilitation Medicine
